Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedcompletion around
- Principal Investigator
- by Jonathan Graf, MD
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Jonathan Graf, MD
Professor, Medicine, School of Medicine. Authored (or co-authored) 32 research publications
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Navidea Biopharmaceuticals
- ID
- NCT05246280
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- Expecting 523 study participants
- Last Updated